中文名稱(chēng):ADM抗體 | 英文名稱(chēng):Rabbit Polyclonal ADM Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 292 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無(wú) | 靶點(diǎn): ADM |
WB | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
IHC | 1/50-1/100 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
FCM | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
Aliases | AM; PAMP |
WB Predicted band size | 20 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Synthetic peptide of human ADM |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse kidney tissue, Mouse lung tissue lysates, Primary antibody: P04680(ADM Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes
The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04680(ADM Antibody) at dilution 1/50. (Original magnification: ×200)
以下是關(guān)于腎上腺髓ullin(ADM)抗體的參考文獻(xiàn)示例(注:內(nèi)容為模擬概括,建議通過(guò)學(xué)術(shù)數(shù)據(jù)庫(kù)驗(yàn)證具體信息):
1. **標(biāo)題**:*Adrenomedullin as a Biomarker in Sepsis: Development of a Novel Immunoassay*
**作者**:Geven, C., et al.
**摘要**:研究開(kāi)發(fā)了一種高靈敏度的ADM抗體檢測(cè)方法,用于膿毒癥患者的早期診斷,發(fā)現(xiàn)血漿ADM水平與疾病嚴(yán)重程度和預(yù)后相關(guān)。
2. **標(biāo)題**:*Therapeutic Potential of Anti-Adrenomedullin Antibody in Hypertensive Disorders*
**作者**:Nishikimi, T., et al.
**摘要**:探討了ADM中和性抗體在高血壓模型中的作用,證明其可通過(guò)調(diào)節(jié)血管舒張功能改善血壓,提示其作為新型降壓療法的潛力。
3. **標(biāo)題**:*Adrenomedullin Antibody Attenuates Tumor Angiogenesis in Mouse Models*
**作者**:Pio, R., et al.
**摘要**:通過(guò)抑制ADM信號(hào)通路,ADM抗體顯著減少了腫瘤血管生成和生長(zhǎng),為癌癥治療提供了實(shí)驗(yàn)依據(jù)。
4. **標(biāo)題**:*Role of ADM Autoantibodies in Preeclampsia Pathogenesis*
**作者**:Li, Y., et al.
**摘要**:發(fā)現(xiàn)子癇前期患者中存在ADM自身抗體,可能與胎盤(pán)功能障礙相關(guān),提示其作為疾病生物標(biāo)志物的可能性。
**提示**:以上為領(lǐng)域內(nèi)典型研究方向示例,實(shí)際文獻(xiàn)需通過(guò)PubMed、Web of Science等平臺(tái)以關(guān)鍵詞(如“adrenomedullin antibody”、“ADM immunoassay”)檢索獲取最新數(shù)據(jù)。
Adrenomedullin (ADM) is a multifunctional peptide hormone initially discovered in 1993. primarily produced by vascular endothelial cells, smooth muscle cells, and various tissues under hypoxic or inflammatory conditions. It plays a critical role in regulating vasodilation, angiogenesis, electrolyte balance, and inflammation. Elevated ADM levels are associated with sepsis, cardiovascular diseases, and cancer, where it often serves as a biomarker for disease severity and prognosis. However, excessive ADM can exacerbate pathological processes, such as promoting vascular leakage in sepsis or tumor progression.
ADM-targeting antibodies have emerged as therapeutic tools to neutralize its harmful effects. These antibodies bind ADM or its receptors (e.g., CLR-RAMP complexes), blocking downstream signaling. In sepsis, preclinical studies show that anti-ADM antibodies may stabilize endothelial barrier function and improve microcirculation. Similarly, in oncology, they are explored for inhibiting ADM-driven tumor growth and metastasis. Diagnostic applications include immunoassays to quantify ADM levels in blood, aiding in early disease detection or monitoring.
Current research focuses on optimizing antibody specificity and delivery, with some candidates in clinical trials. Challenges include balancing ADM’s dual roles (protective vs. pathogenic) and minimizing off-target effects. Despite these hurdles, ADM antibodies represent a promising avenue for precision medicine in critical care and oncology.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(wàn)(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP3年
|
武漢佰樂(lè)博生物技術(shù)有限公司
|
2025-08-06 | |
¥1200 |
VIP3年
|
上海嘉定區(qū)澄瀏公路52號(hào)
|
2025-08-06 | |
詢(xún)價(jià) |
VIP2年
|
廣州弗爾博生物科技有限公司
|
2025-08-06 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |